| Joshua Finney, | |
|
81 Hartwell Ave Ste 310, Lexington, MA 02421-3160 | |
| (478) 363-5840 | |
| Not Available |
| Full Name | Joshua Finney |
|---|---|
| Gender | Male |
| Speciality | Counselor - Mental Health |
| Location | 81 Hartwell Ave Ste 310, Lexington, Massachusetts |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033817812 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YM0800X | Counselor - Mental Health | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Joshua Finney, 285 Hancock St Apt 1424, Quincy, MA 02171-2481 Ph: (478) 363-5840 | Joshua Finney, 81 Hartwell Ave Ste 310, Lexington, MA 02421-3160 Ph: (478) 363-5840 |
News Archive
By considering molecular-level events on a broader scale, researchers now have a clearer, if more complicated, picture of how one class of immune cells goes wrong when loaded with cholesterol. The findings reported in the February 3rd issue of Cell Metabolism, a Cell Press publication, show that, when it comes to the development of atherosclerosis and heart disease, it's not about any one bad actor-it's about a network gone awry.
Boston Therapeutics, Inc. has announced that it has submitted structure and function claims of its SUGARDOWN™ to the US Food and Drug Administration on June 21, 2010.
In an Indoor Air study conducted in a suburb of the city of Kuopio, Finland, relatively short-lasting wood and candle burning of a few hours increased residents' daily exposure to potentially hazardous particulate air pollution.
Nektar Therapeutics today announced positive results from a Phase 2 clinical study evaluating single-agent NKTR-102 in women with platinum-resistant/refractory ovarian cancer. A total of 68 patients were enrolled with platinum-resistant disease, half of whom were platinum refractory. All 68 patients were evaluable for the primary endpoint of objective response rate using Gynecologic Cancer InterGroup criteria, which is a combination of response by tumor imaging (RECIST) and/or ovarian cancer biomarker (CA-125) criteria.
› Verified 9 days ago
Ms. Magi Mckinnies, LMHC Counselor Medicare: Not Enrolled in Medicare Practice Location: 17 Fletcher Ave, Lexington, MA 02420 Phone: 781-860-0620 | |
Denise Moyo, MSW Counselor Medicare: Not Enrolled in Medicare Practice Location: 1040 Waltham St, Lexington, MA 02421 Phone: 781-761-5165 | |
Michael Levi, Counselor Medicare: Not Enrolled in Medicare Practice Location: 221 Waltham St, Lexington, MA 02421 Phone: 339-707-0232 | |
Mr. Kyle Combs, Counselor Medicare: Not Enrolled in Medicare Practice Location: 1040 Waltham St, Lexington, MA 02421 Phone: 774-262-2868 | |
Angeliki Constantine, Counselor Medicare: Not Enrolled in Medicare Practice Location: 125 Hartwell Ave, Lexington, MA 02421 Phone: 781-861-0890 | |
Emma Clay, RN Counselor Medicare: Not Enrolled in Medicare Practice Location: 125 Hartwell Ave, Lexington, MA 02421 Phone: 781-861-0890 | |
Kate Mcgrath, Counselor Medicare: Not Enrolled in Medicare Practice Location: 125 Hartwell Ave, Lexington, MA 02421 Phone: 781-861-0890 |